Intravenous iron dextran treatment in predialysis patients with chronic renal failure

American Journal of Kidney Diseases

Volumn 36, Issue 4, 2000, Pages 775-782

  Dahdah, Khalil ^a   Patrie, James T ^a   Bolton, Warren Kline ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Intravenous iron dextran (IVID); Pre end stage renal disease (pre ESRD)

Indexed keywords

CREATININE; FERRITIN; HEMOGLOBIN; IRON DEXTRAN; TRANSFERRIN;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG COST; DRUG EFFICACY; DYSPNEA; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HYPOTENSION; IRON DEFICIENCY ANEMIA; IRON THERAPY; MALE; MYALGIA; RANDOMIZED CONTROLLED TRIAL; RASH; THORAX PAIN; TREATMENT OUTCOME;

EID: 0033820446     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.17663     Document Type: Article

References (31)

1. Intravenous iron for the treatment of predialysis anemia
2. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin
3. Hypertension and cardiovascular effect - Long-term safety and potential long-term benefits of r-HuEPO
4. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease
5. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialysis patients
6. Hydralazine-associated glomerulonephritis
7. DOQI Clinical Practice Guidelines for the Treatment of Anemia
8. How to get the best of our r-HuEPO
9. Iron status in patients receiving erythropoietin for dialysis-associated anemia
10. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era
11. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin
12. Iron management during recombinant human erythropoietin therapy
13. Intravenous iron supplementation for the treatment of anemia of moderate to severe chronic renal failure patients not receiving dialysis
14. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin
15. How to get the best out of r-HuEPO
16. Safety aspects of parenteral iron in patients with end-stage renal disease
17. Iron management in end-stage renal disease
18. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients
19. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment
20. Intravenous iron supplementation in end-stage renal disease patients
21. Efficacy of bolus intravenous iron dextra treatment in peritoneal dialysis patients receiving recombinant human erythropoietin
22. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO)
23. Parenteral iron supplementation
24. Toxicity of parenteral iron dextran therapy
25. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextran
26. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial
27. Iron deficiency anemiaWhen is parenteral therapy warranted?
28. Effect of intravenous iron dextran on rheumatoid synovitis